CHMP recommends withdrawal of MA for Novartis’s Adakveo® (crizanlizumab)

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended that Adakveo® (crizanlizumab) should no longer be used to prevent painful crises in patients aged 16 years and older with sickle cell disease.  This follows a review by the CHMP, which concluded that the benefits of the medicine did not outweigh its risks.  The CHMP reviewed a clinical trial study which compared the effectiveness and safety of Adakveo® with placebo, and demonstrated that Adakveo® did not lead to a decrease in painful crises when compared to the placebo.